Table 2. Times related to sedative effects after starting intramuscular (IM) or intravenous (IV) administration of alfaxalone-HPCD in cats.
| Alfaxalone administration |
|||||
|---|---|---|---|---|---|
| 1 mg/kg IM | 2.5 mg/kg IM | 5 mg/kg IM | 10 mg/kg IM | 5 mg/kg IV | |
| Time to onset of lateral recumbency (sec) | 451 ± 129* | 213 ± 143d) | 152 ± 85 | 128 ± 22 | 27 ± 14a) |
| Time to the first appearance of spontaneous movement (min) | 15 ± 10* | 27 ± 7c) | 42 ± 12c) | 74 ± 12a, b) | 29 ± 12c) |
| Time to head lift (min) | 22 ± 10* | 40 ± 15b, c) | 75 ± 18a, d) | 100 ± 18a, d) | 48 ± 6b, c) |
| Time to unaided standing (min) | 30 ± 10* | 60 ± 10b, c) | 95 ± 24a, d) | 121 ± 22a, d) | 59 ± 6b, c) |
| Duration of lack of spontaneous movement (min) | 10 ± 11* | 21 ± 8c) | 35 ± 16c) | 72 ± 12a, b) | 29 ± 12c) |
| Duration of maintenance of lateral recumbency (min) | 16 ± 12* | 40 ± 15b, c) | 76 ± 21a, c) | 115 ± 22a, b, d) | 50 ± 5c) |
Data are expressed as mean ± standard deviation. a) Significant difference from 2.5 mg/kg IM (P<0.05). b) Significant difference from 5 mg/kg IM (P<0.05). c) Significant difference from 10 mg/kg IM (P<0.05). d) Significant difference from 5 mg/kg IV (P<0.05). *Statistical analysis was performed among three treatments (IM2.5, IM5 and IM10), because of small samples in the IM1 treatment.